Cargando…
Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
AIMS/INTRODUCTION: Recent clinical trials on sodium–glucose cotransporter 2 inhibitors showed improved outcomes in patients with type 2 diabetes at a high risk of cardiovascular events. However, the underlying effects on endothelial function remain unclear. MATERIALS AND METHODS: The effect of empag...
Autores principales: | Tanaka, Atsushi, Shimabukuro, Michio, Machii, Noritaka, Teragawa, Hiroki, Okada, Yosuke, Shima, Kosuke R., Takamura, Toshinari, Taguchi, Isao, Hisauchi, Itaru, Toyoda, Shigeru, Matsuzawa, Yasushi, Tomiyama, Hirofumi, Yamaoka‐Tojo, Minako, Ueda, Shinichiro, Higashi, Yukihito, Node, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610132/ https://www.ncbi.nlm.nih.gov/pubmed/32537887 http://dx.doi.org/10.1111/jdi.13289 |
Ejemplares similares
-
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2017) -
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2021) -
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
por: Tanaka, Atsushi, et al.
Publicado: (2021) -
Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
por: Sone, Hirohito, et al.
Publicado: (2019) -
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)